Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: A retrospective cohort study.
antiphospholipid syndrome
inflammation
systemic lupus erythematosus
thrombosis
venous thromboembolism
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
31
07
2022
revised:
20
09
2022
accepted:
10
10
2022
entrez:
18
11
2022
pubmed:
19
11
2022
medline:
19
11
2022
Statut:
epublish
Résumé
Recurrence risk of systemic lupus erythematosus (SLE)-associated venous thromboembolism (VTE) is unclear. To determine the recurrence risk of SLE-associated VTE overall and by presence of provoking factors and SLE flares. A multicenter, retrospective cohort study was conducted among patients with first SLE-associated VTE who discontinued anticoagulation. SLE flares were defined as Systemic Lupus Erythematosus Disease Activity Index 2000 greater than 4. The primary outcome was recurrent VTE. Incidence rates and cumulative incidences were calculated by presence of provoking factors and antiphospholipid syndrome (APS) at index VTE. The hazard ratio (HR) for recurrence after SLE flare-associated index VTE was estimated with Cox regression, adjusted for provoking factor presence and APS. Eighty patients were included with 21 recurrent VTEs in median 8 years. For provoked index VTE, the recurrence rate in patients without APS was 1.1 per 100 person-years (PY; 95% confidence interval [CI], 0.1-3.1) and in the presence of APS 3.5 per 100 PY (95% CI, 0.9-8.9), yielding cumulative incidences of 7.5% (95% CI, 1.2%-21.7%) and 31.4% (95% CI, 6.3%-61.6%) respectively. For unprovoked index VTE, these analogous rates were 3.8 per 100 PY (95% CI, 1.2-9.0) and 16.7 per 100 PY (95% CI, 4.5-42.7), with cumulative incidences of 33.7% (95% CI, 10.7%-58.9%) and 54.2% (95% CI, 10.7%-84.5%), respectively. Forty-six index VTEs were flare associated, and the adjusted HR for recurrence was 0.4 (95% CI, 0.1-1.8) compared to those without flares at their index VTE. Antiphospholipid syndrome is the main determinant for recurrence risk of SLE-associated VTE irrespective of presence of a provoking factor. Future research should attempt to confirm that flare-associated VTE has a lower recurrence risk.
Sections du résumé
Background
UNASSIGNED
Recurrence risk of systemic lupus erythematosus (SLE)-associated venous thromboembolism (VTE) is unclear.
Aim
UNASSIGNED
To determine the recurrence risk of SLE-associated VTE overall and by presence of provoking factors and SLE flares.
Methods
UNASSIGNED
A multicenter, retrospective cohort study was conducted among patients with first SLE-associated VTE who discontinued anticoagulation. SLE flares were defined as Systemic Lupus Erythematosus Disease Activity Index 2000 greater than 4. The primary outcome was recurrent VTE. Incidence rates and cumulative incidences were calculated by presence of provoking factors and antiphospholipid syndrome (APS) at index VTE. The hazard ratio (HR) for recurrence after SLE flare-associated index VTE was estimated with Cox regression, adjusted for provoking factor presence and APS.
Results
UNASSIGNED
Eighty patients were included with 21 recurrent VTEs in median 8 years. For provoked index VTE, the recurrence rate in patients without APS was 1.1 per 100 person-years (PY; 95% confidence interval [CI], 0.1-3.1) and in the presence of APS 3.5 per 100 PY (95% CI, 0.9-8.9), yielding cumulative incidences of 7.5% (95% CI, 1.2%-21.7%) and 31.4% (95% CI, 6.3%-61.6%) respectively. For unprovoked index VTE, these analogous rates were 3.8 per 100 PY (95% CI, 1.2-9.0) and 16.7 per 100 PY (95% CI, 4.5-42.7), with cumulative incidences of 33.7% (95% CI, 10.7%-58.9%) and 54.2% (95% CI, 10.7%-84.5%), respectively. Forty-six index VTEs were flare associated, and the adjusted HR for recurrence was 0.4 (95% CI, 0.1-1.8) compared to those without flares at their index VTE.
Conclusion
UNASSIGNED
Antiphospholipid syndrome is the main determinant for recurrence risk of SLE-associated VTE irrespective of presence of a provoking factor. Future research should attempt to confirm that flare-associated VTE has a lower recurrence risk.
Identifiants
pubmed: 36397932
doi: 10.1002/rth2.12839
pii: S2475-0379(22)02434-7
pmc: PMC9663318
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12839Informations de copyright
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
Rheumatology (Oxford). 2011 May;50(5):982-8
pubmed: 21245073
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
J Thromb Haemost. 2016 Jul;14(7):1480-3
pubmed: 27428935
J Thromb Haemost. 2012 Apr;10(4):698-702
pubmed: 22332937
Expert Opin Biol Ther. 2019 Feb;19(2):157-168
pubmed: 30571926
Blood. 2014 Mar 20;123(12):1794-801
pubmed: 24497538
Ann Rheum Dis. 2009 Feb;68(2):238-41
pubmed: 18782792
J Thromb Haemost. 2020 Jun;18(6):1495-1500
pubmed: 32496023
Semin Thromb Hemost. 2019 Mar;45(2):141-149
pubmed: 29954011
Lancet. 2012 Jan 21;379(9812):244-9
pubmed: 22119579
Ann Rheum Dis. 2019 Oct;78(10):1296-1304
pubmed: 31092409
Lancet. 2010 Feb 20;375(9715):657-63
pubmed: 20149425
Lupus. 1999;8(8):638-44
pubmed: 10568901
Br J Haematol. 2020 Sep;190(6):e343-e346
pubmed: 32579233
Br J Haematol. 2021 Jul;194(1):195-199
pubmed: 34075574
Autoimmun Rev. 2014 Nov;13(11):1082-9
pubmed: 25172239